公开(公告)号：US20220241200A1

公开(公告)日：2022-08-04

申请号：US17589639

申请日：2022-01-31

申请人： InSitu Biologics, Inc.

发明人： William J. Taylor

IPC分类号： A61K9/107 ,  A61K31/445 ,  A61K47/12

摘要： Disclosed herein is a composition for treating post-surgical pain comprising: an aqueous carrier; and a lipid phase comprising an anesthetic agent, the lipid phase dispersed within the aqueous carrier. In certain aspects, the aqueous carrier is hydrogel comprised of tyramine substituted hyaluronic acid. In certain embodiments, the hydrogel is formed through di-tyramine crosslinking. In certain embodiments, the degree of tyramine substitution of hyaluronic acid hydroxyl groups is about 0.5% to about 3%. In further aspects, the lipid phase is comprised of a plurality of lipid microparticles. According to certain embodiments, a salt form of the anesthetic unbound by the plurality of lipid microparticles is dissolved in the aqueous carrier.

公开(公告)号：US20190175495A1

公开(公告)日：2019-06-13

申请号：US16300660

申请日：2017-05-12

申请人： InSitu Biologics, Inc.

发明人： William Taylor ,  Daniel Sipple ,  James Segermark

IPC分类号： A61K9/00 ,  A61K31/327 ,  A61K31/738 ,  C12N9/08

摘要： A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.

公开(公告)号：US20240335437A1

公开(公告)日：2024-10-10

申请号：US18631935

申请日：2024-04-10

申请人： InSitu Biologics, Inc.

发明人： William J. Taylor ,  Kelsey Pflepsen

IPC分类号： A61K31/445 ,  A61K9/107 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26

CPC分类号： A61K31/445 ,  A61K9/107 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26

摘要： Disclosed herein is composition for treating pain in a subject in need thereof that comprises an emulsion comprising: an aqueous carrier; and liquid lipid phase dispersed into droplets within the aqueous carrier, and a first anesthetic agent within the lipid phase. In certain embodiments, the first anesthetic agent comprises a first plurality of anesthetic agent crystals. In certain alternative embodiments, the first anesthetic agent is dissolved with the lipid phase. In certain implementations, the composition further comprises a second plurality of anesthetic agent crystals within the aqueous carrier, but not the lipid phase and wherein the second plurality of anesthetic agent crystals dissolves and elutes from the emulsion at a faster rate than the first plurality anesthetic agent crystals. In certain implementations, the composition further comprises one or more additional anesthetic agents, different from the first anesthetic agent.

公开(公告)号：US20240315968A1

公开(公告)日：2024-09-26

申请号：US18615846

申请日：2024-03-25

申请人： inSitu Biologics, Inc.

发明人： William J. Taylor ,  Kelsey Pflepsen

IPC分类号： A61K9/107 ,  A61K9/00 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K47/10 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

CPC分类号： A61K9/107 ,  A61K9/0019 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K47/10 ,  A61K47/24 ,  A61K47/36 ,  A61K47/44

摘要： Disclosed herein is composition for treating a tumor in a subject in need thereof that comprises an emulsion comprising: an aqueous carrier; and liquid lipid phase dispersed into droplets within the aqueous carrier, and a first chemotherapeutic agent within the lipid phase. In certain embodiments, the first chemotherapeutic agent comprises a first plurality of chemotherapeutic agent crystals. In certain alternative embodiments, the first chemotherapeutic agent is dissolved with the lipid phase. In certain implementations, the composition further comprises a second plurality of chemotherapeutic agent crystals within the aqueous carrier, but not the lipid phase and wherein the second plurality of chemotherapeutic agent crystals dissolves and elutes from the emulsion at a faster rate than the first plurality chemotherapeutic agent crystals. In certain implementations, the composition further comprises one or more additional chemotherapeutic agents, different from the first chemotherapeutic agent.

公开(公告)号：US20230256056A1

公开(公告)日：2023-08-17

申请号：US18109028

申请日：2023-02-13

申请人： InSitu Biologics, Inc.

发明人： William J. Taylor ,  Kelsey Pflepsen

IPC分类号： A61K38/18 ,  A61K9/16 ,  A61K31/65

CPC分类号： A61K38/1866 ,  A61K9/1617 ,  A61K31/65 ,  A61K9/1652 ,  A61K9/0019

摘要： Disclosed herein is a composition for treating cancer comprising: an aqueous carrier, wherein the aqueous carrier is hydrogel comprised of tyramine substituted hyaluronic acid, wherein the hydrogel is formed through di-tyramine crosslinking and wherein the degree of tyramine substitution of hyaluronic acid hydroxyl groups is about 0.5% to about 3%; and a lipid phase comprising an antitumor agent, the lipid phase dispersed within the aqueous carrier, wherein the lipid phase comprises a plurality of lipid microparticles.

公开(公告)号：US20230110223A1

公开(公告)日：2023-04-13

申请号：US17965738

申请日：2022-10-13

申请人： InSitu Biologics, Inc.

发明人： William J. Taylor ,  Kelsey Pflepsen ,  Mark Ereth

IPC分类号： A61K31/445 ,  A61K47/12 ,  A61K47/36 ,  A61K9/06 ,  A61K9/107

摘要： In general a hydrogel-lipid-microparticle drug delivery matrix that is tunable and has the ability to deliver sustained release pharmaceutical and / or active agents. The hydrogel-lipid-microparticle drug delivery matrix being echogenic.

公开(公告)号：US20230080761A1

公开(公告)日：2023-03-16

申请号：US17946849

申请日：2022-09-16

申请人： InSitu Biologics, Inc.

发明人： William Taylor ,  Daniel Sipple ,  James Segermark

IPC分类号： A61K9/00 ,  A61K47/36 ,  A61K9/06 ,  A61K31/327 ,  A61K31/738 ,  C12N9/08

摘要： A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.

公开(公告)号：US11471402B2

公开(公告)日：2022-10-18

申请号：US16300660

申请日：2017-05-12

申请人： InSitu Biologics, Inc.

发明人： William Taylor ,  Daniel Sipple ,  James Segermark

IPC分类号： A61K9/00 ,  A61K47/36 ,  A61K9/06 ,  A61K31/327 ,  A61K31/738 ,  C12N9/08

摘要： A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.